Clinically, our results reinforce the paradigm that M1-biased macrophage signatures are associated with favorable prognosis, whereas high burdens of M2/TAM subsets (e.g. CD163+ or EPOR+CD163+ TAMs) predict aggressive disease and metastatic potential in osteosarcoma patients (45, 46). This evidence concerns the gene CD163 and osteosarcoma.